Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes

References

• Babany G., Tinel M., Letteron P., Freneaux E., Berson A., Larrey D., Pessayre D. Inhibitory effects of nilutamide, a new androgen receptor antagonist, on mouse and human liver cytochrome P-450. Biochemical Pharmacology 1989; 38: 941–947
   PubMed Web of Science ®Google Scholar
• Berson A., Wolf C., Berger V., Fau D., Chachaty C., Fromenty B., Pessayre D. Generation of free radicals during the reductive metabolism of the nitroaromatic compound, nilutamide. Journal of Pharmacology and Experimental Therapeutics 1991; 257: 714–719
   PubMed Web of Science ®Google Scholar
• Bertilsson L., Henthorn T. K., Sanz E., Tybring G., Sawe J., Villen T. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clinical Pharmacology and Therapeutics 1989; 45: 348–355
   PubMed Web of Science ®Google Scholar
• Conney A. H. Pharmacological implications of microsomal enzyme induction. Pharmacological Reviews 1967; 19: 317–366
   PubMed Web of Science ®Google Scholar
• Danan G., Descatoire V., Pessayre D. Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. Journal of Pharmacology and Experimental Therapeutics 1981; 218: 509–514
   PubMed Web of Science ®Google Scholar
• Fisher D., Labbe G., Berson A., Tinel M., Loeper J., Larrey D., Pessayre D. Inhibition of rat liver estrogen 2/4-hydroxylase activity by troleandomycin: comparison with erythromycin and roxithromycin. Journal of Pharmacology and Experimental Therapeutics 1990; 254: 1120–1127
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J. Molecular genetics of the P-450 superfamily. Pharmacology and Therapeutics 1990; 45: 1–38
   PubMed Web of Science ®Google Scholar
• Halpert J. R. Multiplicity of steroid-inducible cytochromes P-450 in rat liver microsomes. Archives of Biochemistry and Biophysics 1988; 263: 59–68
   PubMed Web of Science ®Google Scholar
• Helsby N. A., Ward S. A., Howells R. E., Breckenridgf A. M. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P-450 MP) enzyme. British Journal of Clinical Pharmacology 1990; 30: 287–291
   PubMed Web of Science ®Google Scholar
• Jurima M., Inaba T., Kadar D., Kalow W. Genetic polymorphism of mephenytoin p(4′)-hydroxylation: difference between Orientals and Caucasians. British Journal of Clinical Pharmacology 1985; 19: 483–487
   PubMed Web of Science ®Google Scholar
• Knodell R. G., Dubey A. K., Wilkinson G. R., Guengerich F. P. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. Journal of Pharmacology and Experimental Therapeutics 1988; 245: 845–849
   PubMed Web of Science ®Google Scholar
• Kupfer A., Branch R. A. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clinical Pharmacology and Therapeutics 1985; 38: 414–418
   PubMed Web of Science ®Google Scholar
• Kupfer A., Preisig R. Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. European Journal of Clinical Pharmacology 1984; 26: 753–759
   PubMed Web of Science ®Google Scholar
• Kupfer A., Roberts R. K., Schenker S., Branch R. A. Stereoselective metabolism of mephenytoin. Journal of Pharmacology and Experimental Therapeutics 1981; 218: 193–199
   PubMed Web of Science ®Google Scholar
• Kupfer A., Patwardhan R., Ward S., Schenker S., Preisig R., Branch R. A. Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (Nirvanol) in humans. Journal of Pharmacology and Experimental Therapeutics 1984; 230: 28–33
   PubMed Web of Science ®Google Scholar
• Le Dafniet M., Pessayre D., Le Quernec L., Erlinger S. Effects of troleandomycin administration on cholesterol 7α-hydroxylase actvity and bile secretion in rats. Journal of Pharmacology and Experimental Therapeutics 1981; 219: 558–562
   PubMed Web of Science ®Google Scholar
• Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Nagata K., Gonzalez F. G., Yamazoe Y., Kato R. Purification and characterization of four catalytically active testosterone 6β-hydroxylase P-450s from rat liver microsomes: Comparison of a novel form with three structurally and functionally related forms. Journal of Biochemistry 1990; 107: 718–725
   PubMed Web of Science ®Google Scholar
• Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E., Wilkinson G. R., Branch R. A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clinical Pharmacology and Therapeutics 1985; 38: 402–408
   PubMed Web of Science ®Google Scholar
• Nebert D. W., Nelson D. R., Coon M. J., Estabrook R. W., Feyereisen R., Fujii-Kuriyama Y., Gonzalez F. J., Guengerich F. P., Gunsalus I. R., Johnson E. F., Loper J. C., Sato R., Waterman M. R., Waxman D. J. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA and Cell Biology 1991; 10: 1–14
   PubMed Web of Science ®Google Scholar
• Pessayre D., Descatoire V., Tinel M., Larrey D. Self-induction by oleandomycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. Comparison with troleandomycin. Journal of Pharmacology and Experimental Therapeutics 1982; 221: 215–221
   PubMed Web of Science ®Google Scholar
• Raynaud J. P., Bonne C., Bouton M. M., Lagace L., Labrie F. Action of a nonsteroid antiandrogen, RU23908, in peripheral and central tissues. Journal of Steroid Biochemistry 1979; 11: 93–99
   PubMedGoogle Scholar
• Raynaud J. P., Bonne C., Moguilewsky M., Lefebvre F. A., Belanger A., Labrie F. The pure antiandrogen RU23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review. Prostate 1984; 5: 299–311
   PubMed Web of Science ®Google Scholar
• Shimada T., Guengerich F. P. Participation of a rat liver cytochrome P-450 induced by pregnenolone 16α-carbonitrile and other compounds in the 4-hydroxylation of mephenytoin. Molecular Pharmacology 1985; 28: 215–219
   PubMed Web of Science ®Google Scholar
• Shimada T., Misono K. S., Guengerich F. P. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism involved in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. Journal of Biological Chemistry 1986; 261: 909–921
   PubMed Web of Science ®Google Scholar
• Tinel M., Descatoire V., Larrey D., Loeper J., Labbe G., Letteron P., Pessayre D. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. Journal of Pharmacology and Experimental Therapeutics 1989; 250: 746–751
   PubMed Web of Science ®Google Scholar
• Watkins P. B., Wrighton S. A., Schuetz E. G., Maurel P., Guzelian P. S. Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture. Journal of Biological Chemistry 1986; 261: 6264–6271
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Maurel P., Schuetz E. G., Watkins P. B., Young B., Guzelian P. S. Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450p. Biochemistry 1985; 24: 2171–2178
   PubMed Web of Science ®Google Scholar
• Yasumori T., Kawano S., Nagata K., Shimada M., Yamazoe Y., Kato R. Nucleotide sequence of a human liver cytochrome P-450 related to the rat male specific form. Journal of Biochemistry (Tokyo) 1987; 102: 1075–1082
   PubMed Web of Science ®Google Scholar
• Yasumori T., Murayama N., Yamazoe Y., Kato R. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2. Clinical Pharmacology and Therapeutics 1990; 47: 313–322
   PubMed Web of Science ®Google Scholar